A Aforeworn
Forewarned is forearmed.
Home › Niches › Pharmaceutical Manufacturing (FDA/DEA) › Change
Low urgency

Bright Green Corp. Submits DEA Registration For Production of Schedule I, II Controlled Substances - cannabisbusinesstimes.com

Detected August 8, 2026 · in Pharmaceutical Manufacturing (FDA/DEA)

Bright Green Corp. has submitted a DEA registration to produce Schedule I and II controlled substances, signaling potential new competition in the cannabis pharmaceutical market.

Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 8, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing (503B) facilities involved in controlled substances. should confirm how it applies to their specific situation before acting. There is a time constraint attached: No immediate deadline specified.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.

What changed

A new competitor, Bright Green Corp., has applied for DEA registration to produce Schedule I and II controlled substances, which may lead to increased market competition and potential supply changes.

Who it affects

Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing (503B) facilities involved in controlled substances.

What you must do

Monitor DEA registration approvals and assess potential competitive impact on your product portfolio and supply chain.

Deadline

No immediate deadline specified.

Source: https://news.google.com/rss/articles/CBMi_gFBVV95cUxPckFGVWxkZVlpY0Y2bUR1SU5KcEZqbzlTSGhfRVZkUnBPTkM5b1IxNl84Ukc4WTlCaElLV011QzNsdk9CWFRFYjNXcE9qRmlXZU84aGRUYWc3VjlZX294dXBtb3N1SVQ1cnVxaTVNOS1fOEZ0dTFBWHB4enhleVV2WW9sa3JHb0J3ZUFodE5JQndRVE5MNFdndVJTR3dDekdwaldGUHFEYVdmalRfZHd6NXc3eXFHeDZRTHZHX2VOVFdQbU9uaWlZd1Z3Wl9rUHBiX2tKd0xrWGpPZkFOd0pvbm5WaEpVc1FtWG10NWpBaDFKSnFETFZ1b3UtMjZpQQ?oc=5

Never miss a change like this again

Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.

Start your free trial

Related changes in Pharmaceutical Manufacturing (FDA/DEA)